Micro/nanosystems and biomaterials for controlled delivery of antimicrobial and anti-biofilm agents

References

• Ramage G, Rajendran E, Sherry L, et al. Fungal biofilm resistance. Int J Microbiol. 2012:14. doi:10.1155/2012/528521.
   PubMedGoogle Scholar
• Flemming HC, Wingender J, Szewzyk U, et al. Biofilms: an emergent form of bacterial life. Nat Rev Microbiol. 2016;14:563–575.
   PubMed Web of Science ®Google Scholar
• Mah TF. Biofilm-specific antibiotic resistance. Future Microbiol. 2012;7(9):1061–1072.
   PubMed Web of Science ®Google Scholar
• Sharma D, Misba L, Khan AU. Antibiotics versus biofilm: an emerging battleground in microbial communities. Antimicrob Resist Infect Control. 2019;8(1):76.
   PubMedGoogle Scholar
• Olsen I. Biofilm-specific antibiotic tolerance and resistance. Eur J Clin Microbiol Infect Dis. 2015;34:877–886.
   PubMed Web of Science ®Google Scholar
• Blasi F, Page C, Rossolini GM, et al. The effect of N-acetylcysteine on biofilms: implications for the treatment of respiratory tract infections. Resp Med. 2016;17:190–197.
   Google Scholar
• Weers J. Inhaled antimicrobial therapy – barriers to effective treatment. Adv Drug Deliv Rev. 2015;85:24–43.
   PubMed Web of Science ®Google Scholar
• Dhand R. The rationale and evidence for use of inhaled antibiotics to control pseudomonas aeruginosa infection in non-cystic fibrosis bronchiectasis. J Aerosol Med Pulm D. 2017;31(3):121–138.
   PubMed Web of Science ®Google Scholar
• Qvist T, Eickhardt S, Kragh KN, et al. Chronic pulmonary disease with Mycobacterium abscessus complex is a biofilm infection. Eur Respir J. 2015;46(6):1823–1826.
   PubMed Web of Science ®Google Scholar
• Johnson MM, Odell JA. Nontuberculous mycobacterial pulmonary infections. J Thorac Dis. 2014;6:210–220.
   PubMed Web of Science ®Google Scholar
• Hamilos DL. Host-microbial interactions in patients with chronic rhinosinusitis. J Allergy Clin Immun. 2014;133(3):640–653.e4.
   PubMed Web of Science ®Google Scholar
• Patton JS, Byron PR. Inhaling medicines: delivering drugs to the body through the lungs. Nat Rev Drug Discov. 2007;6(1):67–74.
   PubMed Web of Science ®Google Scholar
• Høiby N, Bjarnholt T, Moser C, et al. ESCMID guideline for the diagnosis and treatment of biofilm infections 2014. Clin Microbiol Infect Official Publ European Soc Clin Microbiol Infect Dis. 2015;21 Suppl 1:S1–25.
   PubMed Web of Science ®Google Scholar
• Mah TF, Pitts B, Pellock B, et al. A genetic basis for Pseudomonas aeruginosa biofilm antibiotic resistance. Nature. 2003;426(6964):306–310.
   PubMed Web of Science ®Google Scholar
• Waters V, Smyth A. Cystic fibrosis microbiology: advances in antimicrobial therapy. J Cyst Fibros Official J European Cyst Fibros Soc. 2015;14(5):551–560.
   PubMed Web of Science ®Google Scholar
• Hoppentocht M, Akkerman OW, Hagedoorn P, et al. The Cyclops for pulmonary delivery of aminoglycosides; a new member of the Twincer™ family. Eur J Pharm Biopharm. 2015;90:8–15.
   PubMed Web of Science ®Google Scholar
• Buttini F, Balducci A, Colombo G, et al. Dose administration maneuvers and patient care in tobramycin dry powder inhalation therapy. Int J Pharm. 2018;548(1):182–191.
   PubMedGoogle Scholar
• Tarara TE, Weers JG, Eldon MA, et al., inventors. Novartis AG, assignee. Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use. US8404217B2, March 2013
   Google Scholar
• Konstan M, Flume P, Kappler M, et al. Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: the EAGER trial. J Cyst Fibros. 2011;10(1):54–61.
   PubMed Web of Science ®Google Scholar
• Buttini F, Rossi I, Cuia M, et al. Combinations of colistin solutions and nebulisers for lung infection management in cystic fibrosis patients. Int J Pharm. 2016;502(1–2):242–248.
   PubMedGoogle Scholar
• Flynn RA, Goldman MH, Lovely JR, inventors. Pharmax Limited, assignee. Micronised pharmaceutical compositions. WO2000016745, March, 30, 2000.
   Google Scholar
• Montgomery AB, inventor. Corus Pharma Inc, assignee. Inhalable aztreonam aerosol for treatment and prevention of pulmonary bacterial infections. US7208141B2, April 24, 2007.
   Google Scholar
• Retsch-Bogart GZ, Quittner AL, Gibson RL, et al. Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis. Chest. 2009;135(5):1223–1232.
   PubMed Web of Science ®Google Scholar
• Tullis DE, Burns JL, Retsch-Bogart GZ, et al. Inhaled aztreonam for chronic Burkholderia infection in cystic fibrosis: A placebo-controlled trial. J Cyst Fibros. 2014;13(3):296–305.
   PubMed Web of Science ®Google Scholar
• Yu Q, Griffin EF, Moreau-Marquis S, et al. In vitro evaluation of tobramycin and aztreonam versus Pseudomonas aeruginosa biofilms on cystic fibrosis-derived human airway epithelial cells. J Antimicrob Chemother. 2012;67(11):2673–2681.
   PubMed Web of Science ®Google Scholar
• Tsivkovskii R, Sabet M, Tarazi Z, et al. Levofloxacin reduces inflammatory cytokine levels in human bronchial epithelia cells: implications for aerosol MP-376 (levofloxacin solution for inhalation) treatment of chronic pulmonary infections. Fems Immunol Med Mic. 2010;61(2):141–146.
   PubMedGoogle Scholar
• Geller DE, Flume PA, Griffith DC, et al. Pharmacokinetics and safety of MP-376 (levofloxacin inhalation solution) in cystic fibrosis subjects. Antimicrob Agents Ch. 2011;55(6):2636–2640.
   PubMed Web of Science ®Google Scholar
• https://clinicaltrials.gov/ct2/show/NCT02157922
   Google Scholar
• Khan S, Tøndervik A, Sletta H, et al. Overcoming drug resistance with alginate oligosaccharides able to potentiate the action of selected antibiotics. Antimicrob Agents Ch. 2012;56(10):5134–5141.
   PubMed Web of Science ®Google Scholar
• Marshall LJ, Oguejiofor W, Price R, et al. Investigation of the enhanced antimicrobial activity of combination dry powder inhaler formulations of lactoferrin. Int J Pharmaceut. 2016;514(2):399–406.
   PubMed Web of Science ®Google Scholar
• Wang Q, I G, Hickey D, et al. Azithromycin-loaded respirable microparticles for targeted pulmonary delivery for the treatment of pneumonia. Biomaterials. 2018;160:107–123.
   PubMed Web of Science ®Google Scholar
• Smyth H, Bahamondez-Canas T, Tewes F, et al., inventors. Board of regentes of the university of Texas system, assignee. Antibiofilm formulations and use thereof. WO2019104213A1, May 31, 2019.
   Google Scholar
• Gaurav A, Kothari A, Omar B, et al. Assessment of polymyxin B - doxycycline combination against Pseudomonas aeruginosa in in vitro and in a mouse acute pneumonia model. Int J Antimicrob Agents. 2020;56(1):106022.
   PubMed Web of Science ®Google Scholar
• Percival SL, Hill KE, Williams DW, et al. A review of the scientific evidence for biofilms in wounds. Wound Rep Reg. 2012;20(5):647–657.
   PubMed Web of Science ®Google Scholar
• Bjarnsholt T, Kirketerp-Moller K, Jensen PO, et al. Why chronic wounds will not heal: a novel hypothesis. Wound Rep Reg. 2008;16(1):2–10.
   PubMed Web of Science ®Google Scholar
• Omar A, Wright JB, Schultz G, et al. Microbial biofilms and chronic wounds. Microorganisms. 2017;5(1):9.
   PubMed Web of Science ®Google Scholar
• Bielen K, Jongers BS, Boddaert J, et al. Biofilm-induced Type 2 innate immunity in a cystic fibrosis model of pseudomonas aeruginosa. Front Cell Infect Microbiol. 2017;7:274.
   PubMed Web of Science ®Google Scholar
• Peng K-T, Hsieh -C-C, Huang T-Y, et al. Staphylococcus aureus biofilm elicits the expansion, activation and polarization of myeloid-derived suppressor cells in vivo and in vitro. PLoS ONE. 2017;12(8):e0183271.
   PubMed Web of Science ®Google Scholar
• Bianchera A, Catanzano O, Boateng J, et al. The place of biomaterials in wound healing. In: Boateng J, editor. Therapeutic dressings and wound healing applications. Chap. 15. John Wiley & Sons Ltd; 2020.
   Google Scholar
• World Union of Wound Healing Societies (WUWHS), Florence Congress, Position Document. Management of biofilm. Wounds International 2016
   Google Scholar
• Lynch AS, Abbanat D. New antibiotic agents and approaches to treat biofilm-associated infections. Expert Opin Ther Pat. 2010;20(10):1373–1387.
   PubMed Web of Science ®Google Scholar
• Fulaz S, Vitale S, Quinn L, et al. Nanoparticle–biofilm interactions: the role of the EPS matrix. Trends Microbiol. 2019;27(11):915–926.
   PubMed Web of Science ®Google Scholar
• Li X, Yeh YC, Giri K, et al. Control of nanoparticle penetration into biofilms through surface design. Chem Commun. 2015;51(2):282–285.
   PubMed Web of Science ®Google Scholar
• Liu Y, Shi L, Su L, et al. Nanotechnology-based antimicrobials and delivery systems for biofilm-infection control. Chem Soc Rev. 2019;48(2):428–446.
   PubMed Web of Science ®Google Scholar
• Peulen TO, Wilkinson KJ. Diffusion of nanoparticles in a biofilm. Environ Sci Technol. 2011;45(8):3367–3373.
   PubMed Web of Science ®Google Scholar
• Harper RA, Carpenter GH, Proctor GB, et al. Diminishing biofilm resistance to antimicrobial nanomaterials through electrolyte screening of electrostatic interactions. Colloids Surf B Biointerfaces. 2019;173:392–399.
   PubMed Web of Science ®Google Scholar
• Dong D, Thomas N, Thierry B, et al. Distribution and inhibition of liposomes on staphylococcus aureus and pseudomonas aeruginosa biofilm. PLOS One. 2015;10(6):e0131806.
   PubMed Web of Science ®Google Scholar
• Chen CW, Hsu CY, Lai SM, et al. Metal nanobullets for multidrug resistant bacteria and biofilms. Adv Drug Deliv Rev. 2014;78:88–104.
   PubMed Web of Science ®Google Scholar
• Guo J, Qin S, Wei Y, et al. Silver nanoparticles exert concentration‐dependent influences on biofilm development and architecture. Cell Prolif. 2019;52(4):e12616.
   PubMed Web of Science ®Google Scholar
• Mu H, Tang J, Liu Q, et al. Potent antibacterial nanoparticles against. Biofilm Intracell Bact Sci Rep. 2016;6:18877.
   Google Scholar
• Gounani Z, Asadollahi MA, Pedersen JN, et al. Mesoporous silica nanoparticles carrying multiple antibiotics provide T enhanced synergistic effect and improved biocompatibility. Colloids Surf B Biointerfaces. 2019;175:498–508.
   PubMed Web of Science ®Google Scholar
• Chavez de Paz L, Resin A, Howard KA. Antimicrobial effect of chitosan nanoparticles on streptococcus mutants biofilms. App Environ Micrbiol. 2011;77(11):3892–3895.
   PubMed Web of Science ®Google Scholar
• Baier G, Cavallaro A, Vasileva K, et al. Enzyme responsive hyaluronic acid nanocapsules containing polyhexanide and their exposure to bacteria to prevent infection. Biomacromolecules. 2013;14(4):1103–1112.
   PubMed Web of Science ®Google Scholar
• Chu Z, Zhao T, Fan J, et al. Characterization of antimicrobial poly (lactic acid)/nano-composite films with silver and zinc oxide nanoparticles. Materials (Basel). 2016;10(6):659.
   Web of Science ®Google Scholar
• Baelo A, Levato R, Juliàn E, et al. Disassembling bacterial extracellular matrix with DNase-coated nanoparticles to enhance antibiotic delivery in biofilm infections. J Control Rel. 2015;209:150–158.
   PubMed Web of Science ®Google Scholar
• Habimana O, Zanoni M, Vitale S, et al. One particle, two targets. A combined action of functionalized gold nanoparticles, against Pseudomonas fluorescens biofilms. J Coll Interf Sci. 2018;526:419–428.
   PubMed Web of Science ®Google Scholar
• Tran TT, Vidaillac C, Yu H, et al. A new therapeutic avenue for bronchiectasis: dry powder inhaler of ciprofloxacin nanoplex exhibits superior ex vivo mucus permeability and antibacterial efficacy to its native ciprofloxacin counterpart. Int J Pharmaceut. 2018;547:368–376.
   PubMed Web of Science ®Google Scholar
• Wan B, Zhu Y, Tao J, et al. Alginate lyase guided silver nanocomposites for eradicating pseudomonas aeruginosa from lungs. Acs Appl Mater Inter. 2020;12(8):9050–9061.
   PubMed Web of Science ®Google Scholar
• Hair BB, Conley ME, Wienclaw TM, et al. Synergistic activity of silver nanoparticles and vancomycin against a spectrum of staphylococcus aureus biofilm types. Biorxiv 337436. 2018. DOI:10.1101/337436.
   Google Scholar
• D’Angelo I, Casciaro B, Miro A, et al. Overcoming barriers in Pseudomonas aeruginosa lung infections: engineered nanoparticles for local delivery of a cationic antimicrobial peptide. Colloids Surf B Biointerfaces. 2015;135:717–725.
   PubMed Web of Science ®Google Scholar
• Cheow WS, Chang MW, Hadinoto K. The roles of lipid in anti-biofilm efficacy of lipid–polymer hybrid nanoparticles encapsulating antibiotics. Coll Surf Physicochem Eng Aspect. 2011;389(1–3):158–165.
   Web of Science ®Google Scholar
• Sanders NN, De Smedt SC, Van Rompaey E, et al. Cystic Fibrosis Sputum: a barrier to the transport of nanospheres. Am J Resp Crit Care. 2000;162(5):1905–1911.
   PubMed Web of Science ®Google Scholar
• Chono S, Tanino T, Seki T, et al. Influence of particle size on drug delivery to rat alveolar macrophages following pulmonary administration of ciprofloxacin incorporated into liposomes. J Drug Target. 2008;14:557–566.
   Web of Science ®Google Scholar
• Ernst J, Klinger-Strobel M, Arnold K, et al. Polyester-based particles to overcome the obstacles of mucus and biofilms in the lung for tobramycin application under static and dynamic fluidic conditions. Eur J Pharm Biopharm Off J Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik E V. 2018;131:120–129.
   PubMed Web of Science ®Google Scholar
• Miller JK, Neubig E, Clemons CB, et al. Nanoparticle deposition onto biofilms. Ann Biomed Eng. 2012;41(1):53–67.
   PubMed Web of Science ®Google Scholar
• Vyas SP, Sihorkar V, Jain S. Mannosylated liposomes for bio-film targeting. Int J Pharmaceut. 2007;330(1–2):6–13.
   PubMed Web of Science ®Google Scholar
• Robinson AM, Bannister M, Creeth JE, et al. The interaction of phospholipid liposomes with mixed bacterial biofilms and their use in the delivery of bactericide. Coll Surf Physicochem Eng Aspect. 2001;186(1–2):43–53.
   Web of Science ®Google Scholar
• Patel KK, Tripathi M, Pandey N, et al. Alginate lyase immobilized chitosan nanoparticles of ciprofloxacin for the improved antimicrobial activity against the biofilm associated mucoid P. aeruginosaPA infection in cystic fibrosis. Int J Pharmaceut. 2019;563:30–42.
   PubMed Web of Science ®Google Scholar
• Wan F, Bohr SSR, Klodzinska SN, et al. Ultrasmall TPGS-PLGA hybrid nanoparticles for site-specific delivery of antibiotics into pseudomonas aeruginosa biofilms in lungs. Acs Appl Mater Inter. 2019;12(1):380–389.
   PubMed Web of Science ®Google Scholar
• Kłodzińska SN, Wan F, Jumaa H, et al. Utilizing nanoparticles for improving anti-biofilm effects of azithromycin: a head-to-head comparison of modified hyaluronic acid nanogels and coated poly (lactic-co-glycolic acid) nanoparticles. J Colloid Interf Sci. 2019;555:595–606.
   PubMed Web of Science ®Google Scholar
• Sharifi S, Hajipour MJ, Gould L, et al. Nanomedicine in healing chronic wounds: opportunities and challenges. Mol Pharm. 2020. DOI:10.1021/acs.molpharmaceut.0c00346.
   PubMedGoogle Scholar
• Kim MH. Nanoparticle-based therapies for wound biofilm infection: opportunities and challenges. IEEE Trans Nanobioscience. 2016;15(3):294–304.
   Google Scholar
• Grande R, Sisto F, Puca V, et al. Antimicrobial and antibiofilm activities of new synthesized silver ultra-nanoclusters (SUNCs) against helicobacter pylori. Front Microbiol. 2020;11:1705.
   PubMed Web of Science ®Google Scholar
• Yee A, Rosenzweig L, Disckson MN, et al., inventors. The Regents of the University of California, assignee. Novel anti-bacterial anti-fungal nanopillared surface US20190076573A1 March 14, 2019.
   Google Scholar
• Klein J, Lin W, Goldberg R, inventors. Yeda Research and Development Co. assignee. Lipid analogs and liposomes comprising same. WO2017109784, December 12, 2016.
   Google Scholar
• Boluk Y, Liu Y, Sun X, inventors. The Governors of the University of Alberta, assignee. Nanocrystalline cellulose hydrogels for inhibition of bacterial adhesion. US2016346436A1,December 1, 2016.
   Google Scholar
• Miller L, Mao HQ, Ashbaugh A et al. inventors. The Johns Hopkins University, assignee. Compositions and methods for preparation of composite polymer films on non-conducting substrates, including bandages, and their use for treating wounds. WO2020037218A1, February 20, 2020.
   Google Scholar
• Ashbaugh AG, Jiang X, Zheng J, et al. Polymeric nanofiber coating with tunable combinatorial antibiotic delivery prevents biofilm-associated infection in vivo. PNAS. 2016;113(45):E6919–E6928.
   PubMed Web of Science ®Google Scholar
• Dolan RM, Lehman SM, Garcia AJ, inventors. The Government of the United States of America-Georgia Tech research corporation, applicant. Controlled covalent attachment of bioactive bacteriophages for regulating biofilm development. WO2013048604A2, April 4, 2013.
   Google Scholar
• Sauer K, Doiron AL, inventors. The Research Foundation for the State University of New York, applicant. Compositions and methods for disrupting biofilm formation and maintenance. US20190365868A1, December 12, 2019.
   Google Scholar
• Han C, Goodwine J, Romero N, et al. Enzyme-encapsulating polymeric nanoparticles: a potential adjunctive therapy in Pseudomonas aeruginosa biofilm-associated infection treatment. Colloids Surf B Biointerfaces. 2019;184:110512.
   PubMed Web of Science ®Google Scholar
• Iyer AK, Sau S, Rybak M, et al., inventors. Wayne state University, applicant. Drug delivery systems for treatment of infections. WO2019133916A1, July 4, 2019.
   Google Scholar
• Bhise K, sau S, Kebriaei R, et al. Combination of vancomycin and cefazolin lipid nanoparticles for overcoming antibiotic resistance of MRSA. Materials. 2018;11(7):1245.
   PubMed Web of Science ®Google Scholar
• Loo SCJ, Baek J, Tan CH, inventors. Nanyang technological university, National University of Singapore, applicants. Lipid-polymer hybrid nanoparticles. WO2019135715A1, July 11, 2019.
   Google Scholar
• Schoenfisch MH, Reighard K, inventors. The University of North Carolina at Chapel Hill, assignee. Compounds, compositions and methods for inhibiting a pathogen and/or modifying mucus. US2020085858A1, March 9, 2020.
   Google Scholar
• Barraud N, Hassett DJ, Hwang SH, et al. Involvement of nitric oxide in biofilm dispersal of pseudomonas aeruginosa. J Bacteriol. 2006;188(21):7344–7353.
   PubMed Web of Science ®Google Scholar
• Boyer CAJM, Barraud N, Duong HTT, inventors. Newsouth innovations PTY limited, assignee, Anti-biofilm polymer. WO2015139079A1, September 24, 2015.
   Google Scholar
• Schairer DO, Chouake JS, Nosanchuk JD, et al. The potential of nitric oxide releasing therapies as antimicrobial agents. Virulence. 2012;3(3):271–279.
   PubMed Web of Science ®Google Scholar
• Handa H, Pant J, inventors. University of Georgia research foundation assignee. Antimicrobial compositions with wound healing properties. WO2019236825A1, December 12, 2019.
   Google Scholar
• Meledandri CJ, Schwass DR, Cotton CG, et al., inventorse. Otago Innovation Limited, assignee. Antimicrobial gel containing silver nanoparticles. WO2017061878A1, April 13, 2017..
   Google Scholar
• Seo DK, Haydel S Antimicrobial geopolymer compositions. WO2018013830A1, January 18, 2018.
   Google Scholar
• Zale SE, inventor. Pfizer Inc. assignee. Therapeutic nanoparticles comprising an antibiotic and methods of making and using same. WO2017089942A1, June 1, 2017.
   Google Scholar
• Hilliard C, Cast WR Methods to prevent tissue colonization of pathogens and for treatment of biofilms on animal tissues. WO2016187391A1, November 24, 2016.
   Google Scholar
• Hilliard C, William R. Cast. Product and delivery system for application of antimicrobial treatment designed to inhibit pathogens from entering or leaving a respiratory system and to remove pathogens from wounds, ears or other body cavities and methods of use. US20150328240A1, November 19, 2015.
   Google Scholar
• Bakaletz LO, Goodman SD, inventors. Research institute at National Children’s hospital, applicant. Peptides and antibodies for the removal of biofilms. WO2017023863A1, February 9, 2017.
   Google Scholar
• Rhinotopic LLC. Bioadhesive and biodegradable and formulations that provide sustained release of antimicrobials, bacteriophages and anti-inflammatory medications for inactivation of biofilms and the treatment of rhinosinusitis and other infections. US2016022595A1, January 28, 2016.
   Google Scholar
• Weers J, inventor. Insmed Inc. assignee. Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof. US8226975B2, July 24, 2012.
   Google Scholar
• Waters V, Smyth A. Cystic fibrosis microbiology: advances in antimicrobial therapy. J Cyst Fibros Official J European Cyst Fibros Soc. 2015;14(5):551–560.
   PubMed Web of Science ®Google Scholar
• Cipolla DC, Blanchard J inventors. Aradigm corporation. Dual action, inhaled formulations providing both an immediate and sustained release profile. US20120282328A1, November 8, 2012.
   Google Scholar
• Haworth C, Wanner A, Froehlich J, et al. Inhaled liposomal ciprofloxacin in patients with bronchiectasis and chronic Pseudomonas aeruginosa infection: results from two parallel phase iii trials (orbit-3 And-4). Am J Resp Crit Care Med. 2017;195:A7604.
   Google Scholar
• https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-linhaliq_en.pdf
   Google Scholar
• Cipolla D, Blanchard J, Gonda I. Development of liposomal ciprofloxacin to treat lung infections. Pharm. 2016;8:6.
   Google Scholar
• Ambati S, Meagher RB, Lewis Z, et al., inventors. University of Georgia Research foundation assignee. Targeted nanoparticles and their uses related to fungal infections. WO2020146514A1, July 16, 2020.
   Google Scholar
• Millenbaugh N, inventor. The United States of America Represented by the Secretary of Navy, assignee. Method of treating multi-drug resistance biofilm using targeted laser and antibiotics. US20190255349A1, August 22, 2019.
   Google Scholar
• Braeckmans K, Coenye T, Demeester J, et al., inventors. Universiteit Gent, assignee. Disruption or alteration of microbiological films. WO2017009039A1, January 19, 2017.
   Google Scholar
• Sawyer A, Stockel RF, inventors. Nevada Naturals Inc. assignee. Biofilm penetrating compositions and methods. WO2018201119A1, November 1, 2018.
   Google Scholar
• Thomas ND, Richter K, Prestidge CA, inventors. University of South Australia, assignee. Antimicrobial compositions and methods of use. WO2019036770A1, February 28, 2019.
   Google Scholar
• Luukko K, Nuopponen M, Curzio N, et al., inventors. UPM-KYMMENE Corporation, assignee. A medical product comprising bioactive molecule immobilized to nanofibrillar cellulose and method for preparing thereof. WO2019166606A1, September 6, 2019.
   Google Scholar
• Mohapatra SS, Limayem A Compositions for treating drug resistant bacteria and biofilm. US20190134086, A1 May 9, 2019.
   Google Scholar
• Mehta M, Allen-Gipson D, Mohapatra S, et al. Study on the therapeutic index and synergistic effect of Chitosan-zinc oxide nanomicellar composites for drug-resistant bacterial biofilm inhibition. Int J Pharm. 2019;565(April):472–480.
   PubMedGoogle Scholar
• Theivendran S, Kubinec JJ, Smith TR Functional nanoparticle composite comprising chitosan. US2016369065A1, December 22, 2016.
   Google Scholar
• Benoit D, Koo H, inventors. University of Rochester, assignee. Nanoparticles for controlled release of anti-biofilm agents and methods of use. WO2018026764A1, February 8, 2018.
   Google Scholar
• Mohapatra A, Harris MA, Morshed BI, et al., inventors. The University of Memphis research foundation, assignee. Microbead compositions an methods for delivering an agent. WO2018064150A1, April 5, 2018.
   Google Scholar
• Yeoman RR, Winchurch RA, inventors. NanoDERM sciences Inc, assignee. Targeted nanoparticles. US2018028684A1, February 1, 2018.
   Google Scholar
• Abbott NL, McAnulty JF Methods and compositions for wound healing. WO2020037211A1, February 20, 2020.
   Google Scholar
• Kaplan DL, Panilaitis B, Pritchard EM et al. Silk fibroin systems for antibiotic delivery. US2012052124A1, March 1, 2012.
   Google Scholar
• Pritchard EM, Valentin T, Panilaitis B, et al. Antibiotic-releasing silk biomaterials for infection prevention and treatment. Adv Funct Mater. 2013;23(7):854–861.
   PubMed Web of Science ®Google Scholar
• Mahmoudi M. Nanofibrous scaffolds to heal chronic skin wounds. WO2019222511A1, November 21, 2019.
   Google Scholar
• Rotello VM, Landis RF, inventors.The University of Massachussetts, assignee. Crosslinked particles, composition comprising the crosslinked particles, method for the manufacture thereof, and method of treating an infection. WO2019118444A1, June 20, 2019.
   Google Scholar
• Duncan B, Li X, Rotello VM, inventors. The University of Massachussetts, assignee. Nanoparticle-stabilized microcapsules, dispersions comprising nanoparticle-stabilized microcapsules, and method for the treatment of bacterial biofilms. US10272126B2, April 30, 2019.
   Google Scholar
• Bianchera A, Bettini R. Polysaccharide nanoparticles for oral controlled drug delivery: the role of drug-polymer and interpolymer interactions. Exp Opin Drug Deliv. 2020;1–15. DOI:10.1080/17425247.2020.1789585
   PubMed Web of Science ®Google Scholar